• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.

作者信息

Fania L, Di Zenzo G, Mazzanti C, Abeni D

机构信息

Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.

出版信息

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.

DOI:10.1111/jdv.14965
PMID:29569809
Abstract
摘要

相似文献

1
Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.关于“大疱性类天疱疮中糖尿病患病率的变化：是二肽基肽酶 -4 抑制剂所致”的评论
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.
2
Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study".关于“除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究”的评论
J Am Acad Dermatol. 2018 Dec;79(6):e111-e112. doi: 10.1016/j.jaad.2018.06.043.
3
Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'".回复：“对‘除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究’的评论”
J Am Acad Dermatol. 2018 Dec;79(6):e113-e114. doi: 10.1016/j.jaad.2018.06.042.
4
[Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal].大疱性类天疱疮与二肽基肽酶-4抑制剂之间的关联及其撤药的影响
Aten Primaria. 2023 Apr;55(4):102586. doi: 10.1016/j.aprim.2023.102586. Epub 2023 Feb 24.
5
Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid.合并用药与二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
An Bras Dermatol. 2021 Nov-Dec;96(6):782-784. doi: 10.1016/j.abd.2020.10.010. Epub 2021 Sep 30.
6
Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database.
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e879-e881. doi: 10.1111/jdv.18975. Epub 2023 Feb 27.
7
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.与使用二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.
8
Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.
J Am Acad Dermatol. 2019 Jun;80(6):e189-e190. doi: 10.1016/j.jaad.2019.01.086. Epub 2019 Feb 7.
9
Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.二肽基肽酶-4抑制剂诱发大疱性类天疱疮并伴有获得性反应性穿通性皮病
Actas Dermosifiliogr. 2022 Oct;113(9):914-915. doi: 10.1016/j.ad.2021.01.023. Epub 2022 May 27.
10
Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.病例报告：二肽基肽酶-4 抑制剂相关性大疱性类天疱疮发病后出现多种疾病特异性抗体
Front Immunol. 2022 Mar 3;13:843480. doi: 10.3389/fimmu.2022.843480. eCollection 2022.

引用本文的文献

1
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.
2
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.二肽基肽酶-4 抑制剂治疗的糖尿病患者并发大疱性类天疱疮：硬币的另一面。
J Transl Med. 2021 Dec 20;19(1):520. doi: 10.1186/s12967-021-03192-8.
3
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.
二肽基肽酶-4抑制剂相关非炎症性大疱性类天疱疮的临床、实验室及组织学特征
J Clin Med. 2021 Apr 28;10(9):1916. doi: 10.3390/jcm10091916.